Tag: Hua Medicine

First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. Since the launch of commercial sales at the end...

Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class...

Figure 1 <img src="https://www.businessnewsasia.com/wp-content/uploads/2020/06/HuaMed2-300x36.jpg" alt="HbA1c Reduction *p HbA1c Reduction *p Hua Medicine (the "Company",...

Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. HMM0112...

Pivotal Phase III Trial Achieved Clinical Efficacy Endpoint at 24 WeeksDorzagliatin-Driven Portfolio Expands Hua Medicine (the "Company", Stock Code...

Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has joined Hua...